# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The notes will be general unsecured obligations of the Issuer and will accrue interest payable semiannually in arrears on March...
Jazz Pharmaceuticals, together with its consolidated subsidiaries, expects to use a portion of the net proceeds to prepay up to...
Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced top-line results from the Phase 3 open-label, single-arm trial in Japan ...
JP Morgan analyst Jessica Fye maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target fro...